1. Huang S. On the intrinsic inevitability of cancer: from foetal to fatal attraction // Semin. Cancer Biol. 2011. Vol. 21. P. 183–199.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation // Cell. 2011. Vol. 144. P. 646–674.
3. Carette J.E., Pruszak J., Varadarajan M., Blomen V.A., Gokhale S., Camargo F.D. et al. Generation of iPSCs from cultured human malignant cells // Blood. 2010. Vol. 115. P. 4039–4042.
4. Hochedlinger K., Blelloch R., Brennan C., Yamada Y., Kim M., Chin L. et al. Reprogramming of a melanoma genome by nuclear transplantation // Genes Dev. 2004. Vol. 18. P. 1875–1885.
5. McClellan J.S., Dove C., Gentles A.J., Ryan C.E., Majeti R. Reprogramming of primary human Philadelphia chromosomepositive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages // Proc. Natl Acad. Sci. USA. 2015. Vol. 112. P. 4074–4079.
6. Cavalli G., Heard E. Advances in epigenetics link genetics to the environment and disease // Nature. 2019. Vol. 571. P. 489–499.
7. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors // Cell. 2007. Vol. 131. P. 861–872.
8. Teng I.W., Hou P.C., Lee K.D., Chu P.Y., Yeh K.T., Jin V.X. et al. Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells // Cancer Res. 2011. Vol. 71. P. 4653–4663.
9. Russo V.E.A., Martienssen R.A., Riggs A.D. Epigenetic Mechanisms of Gene Regulationed. Cold Spring Harbor Laboratory Press, 1996.
10. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome // Cell. 2007. Vol. 128. P. 669–681.
11. Mikkelsen T.S., Ku M., Jaffe D.B., Issac B., Lieberman E., Giannoukos G. et al. Genomewide maps of chromatin state in pluripotent and lineagecommitted cells // Nature. 2007. Vol. 448. P. 553–560.
12. Aran D., Sabato S., Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes // Genome Biol. 2013. Vol. 14. P. R21.
13. Doni Jayavelu N., Jajodia A., Mishra A., Hawkins R.D. Candidate silencer elements for the human and mouse genomes // Nat. Commun. 2020. Vol. 11. P. 1061.
14. Flavahan W.A., Drier Y., Liau B.B., Gillespie S.M., Venteicher A.S., StemmerRachamimov A.O. et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas // Nature. 2016. Vol. 529. P. 110–114.
15. Herold M., Bartkuhn M., Renkawitz R. CTCF: insights into insulator function during development // Development. 2012. Vol. 139. P. 1045–1057.
16. Rowley M.J., Corces V.G. Organizational principles of 3D genome architecture // Nat. Rev. Genet. 2018. Vol. 19. P. 789–800.
17. Zheng H., Xie W. The role of 3D genome organization in development and cell differentiation // Nat. Rev. Mol. Cell Biol. 2019. Vol. 20. P. 535–550.
18. Wang L.Q., Wong K.Y., Li Z.H., Chim C.S. Epigenetic silencing of tumor suppressor long noncoding RNA BM742401 in chronic lymphocytic leukemia // Oncotarget. 2016. Vol. 7. P. 82 400–82 410.
19. Wang L.Q., Kwong Y.L., Kho C.S., Wong K.F., Wong K.Y., Ferracin M. et al. Epigenetic inactivation of miR9 family microRNAs in chronic lymphocytic leukemia – implications on constitutive activation of NFkappaB pathway // Mol. Cancer. 2013. Vol. 12. P. 173.
20. Wang L.Q., Kwong Y.L., Wong K.F., Kho C.S., Jin D.Y., Tse E. et al. Epigenetic inactivation of mir-34b/c in addition to mir34a and DAPK1 in chronic lymphocytic leukemia // J. Transl. Med. 2014. Vol. 12. P. 52.
21. Wang L.Q., Wong K.Y., Rosen A., Chim C.S. Epigenetic silencing of tumor suppressor miR3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways // Oncotarget. 2015. Vol. 6. P. 44 422–44 436.
22. Wong K.Y., Yim R.L., Kwong Y.L., Leung C.Y., Hui P.K., Cheung F. et al. Epigenetic inactivation of the MIR1292 in hematological malignancies // J. Hematol. Oncol. 2013. Vol. 6. P. 16.
23. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs // Nature. 2008. Vol. 455. P. 58–63.
24. Baylin S.B., Jones P.A. Epigenetic determinants of cancer // Cold Spring Harb. Perspect. Biol. 2016. Vol. 8, N 9. Article ID a019505.
25. Strahl B.D., Allis C.D. The language of covalent histone modifications // Nature. 2000. Vol. 403. P. 41–45.
26. Mohammad H.P., Barbash O., Creasy C.L. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer // Nat. Med. 2019. Vol. 25. P. 403–418.
27. Biswas S., Rao C.M. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy // Eur. J. Pharmacol. 2018. Vol. 837. P. 8–24.
28. StewartMorgan K.R., Petryk N., Groth A. Chromatin replication and epigenetic cell memory // Nat. Cell Biol. 2020. Vol. 22, N 4. P. 361–371.
29. GardinerGarden M., Frommer M. CpG islands in vertebrate genomes // J. Mol. Biol. 1987. Vol. 196. P. 261–282.
30. Skvortsova K., Stirzaker C., Taberlay P. The DNA methylation landscape in cancer // Essays Biochem. 2019. Vol. 63. P. 797–811.
31. Doi A., Park I.H., Wen B., Murakami P., Aryee M.J., Irizarry R. et al. Differential methylation of tissue and cancerspecific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts // Nat. Genet. 2009. Vol. 41. P. 1350–1353.
32. Gray S.G. (ed.). Epigenetic Cancer Therapy. Amsterdam, etc. : Academic Press, 2015. 748 p.
33. Li E., Beard C., Jaenisch R. Role for DNA methylation in genomic imprinting // Nature. 1993. Vol. 366. P. 362–365.
34. Maunakea A.K., Nagarajan R.P., Bilenky M., Ballinger T.J., D’Souza C., Fouse S.D. et al. Conserved role of intragenic DNA methylation in regulating alternative promoters // Nature. 2010. Vol. 466. P. 253–257.